A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 in Combination With Radiation Plus Temozolomide or Temozolomide Alone for Subjects With Glioblastoma Multiforme

Inclusion Criteria:

1. Glioblastoma Multiforme (GBM)

2. 70 or above on Karnofsky Performance Status

3. Adequate bone marrow function

4. For Arm A, subject has newly diagnosed GBM and prior surgical resection

5. For Arm B, subject has newly diagnosed GBM and has completed adjuvant radiation
and/or temozolomide therapy or has recurrent GBM per RANO Criteria

Exclusion Criteria:

1. For subjects with newly diagnosed GBM, subject has received prior chemotherapy or
radiotherapy for cancer of head and neck region

2. For Subjects with recurrent GBM in Arm B, subject has received prior treatment with
bevacizumab, nitrosourea, more than 2 therapies, or has secondary GBM

3. Allergies to temozolomide, dacarbazine, IgG containing agents

4. Anti-cancer treatment 28 days prior to study Day 1